Nuvation Bio reports Q3 2026 revenue of $45M, IBTROZI product revenue up 18% sequentially
Nuvation Bio Inc. announced third‑quarter 2026 total revenue of $45.0 million, of which $27.5 million came from its ROS1 inhibitor IBTROZI®. The drug posted an 18% quarter‑over‑quarter increase in net product revenue. The FDA also approved a supplemental NDA that extends IBTROZI’s label to show a median duration of response of 49.7 months in TKI‑naïve patients, and granted Fast Track Designation to the investigational drug safusidenib for IDH1‑mutant glioma. The company held $663.4 million in cash, cash equivalents and marketable securities at quarter‑end.
Why it matters
The revenue growth and strong cash balance give the company runway to fund ongoing clinical programs and pursue European approval, which could add a $30 million milestone. Analysts note that the label update and market‑leadership data support IBTROZI’s positioning as the standard of care in ROS1‑positive NSCLC.
Key facts
- 1Total Q3 2026 revenue was $45.0 million. prnewswire.com
- 2IBTROZI net product revenue was $27.5 million, an 18% sequential increase. prnewswire.com
- 3The FDA approved a supplemental NDA for IBTROZI, updating the label to a median duration of response of 49.7 months in TKI‑naïve patients. prnewswire.com
- 4The FDA granted Fast Track Designation to safusidenib for IDH1‑mutant glioma. prnewswire.com
- 5Cash, cash equivalents and marketable securities totaled $663.4 million as of September 30, 2026. prnewswire.com
- 6New patient starts in Q3 remained around 160, with 65% being TKI‑naïve. sec.gov
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.